189 related articles for article (PubMed ID: 26391142)
1. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.
Zhan YY; Liang BQ; Li XY; Gu EM; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):439-44. PubMed ID: 26391142
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
3. Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Khan A; Aljenobi FI; Ali N; Al-Mohizea AM
J Food Drug Anal; 2019 Jan; 27(1):332-338. PubMed ID: 30648588
[TBL] [Abstract][Full Text] [Related]
4. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
[TBL] [Abstract][Full Text] [Related]
5. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
6. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.
Bedada SK; Nearati P
Phytother Res; 2015 May; 29(5):701-6. PubMed ID: 25624269
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro.
Wang P; Hu XX; Li YH; Gao NY; Chen GQ; Chen JL
Can J Physiol Pharmacol; 2021 Aug; 99(8):821-826. PubMed ID: 33400617
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS.
Wen J; Bao SS; Zhang BW; Liu TH; Ou-Yang QG; Cai JP; Zhou HY
Drug Dev Ind Pharm; 2019 Jan; 45(1):27-31. PubMed ID: 30156133
[TBL] [Abstract][Full Text] [Related]
9. Investigation of CYP3A4 and CYP2D6 Interactions of Withania somnifera and Centella asiatica in Human Liver Microsomes.
Savai J; Varghese A; Pandita N; Chintamaneni M
Phytother Res; 2015 May; 29(5):785-90. PubMed ID: 25684704
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro.
Zhan YY; Liang BQ; Gu EM; Hu XX; Lin D; Hu GX; Zheng ZQ
Pharmacology; 2015; 96(3-4):118-23. PubMed ID: 26202346
[TBL] [Abstract][Full Text] [Related]
11. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes.
Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z
Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363
[TBL] [Abstract][Full Text] [Related]
12. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
[TBL] [Abstract][Full Text] [Related]
13. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
19. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.
Sawant Basak A; Byon W; Tseng-Lovering E; Funk C; Wood L; Lin C; Delnomdedieu M; Verhoest P; Parikh V; Cox LM; Miller E; Gao H; Obach RS
Xenobiotica; 2014 May; 44(5):438-54. PubMed ID: 24304147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
